SPOTLIGHT: Cancer drug flunks Phase III


BioNumerik Pharmaceuticals and ASKA Pharmaceutical said that a late-stage trial of Tavocept failed to produce a statistically significant response in patients with advanced non-small cell lung cancer. Researchers say that the small number of patients in the trial was probably responsible for the failure, though it highlighted the fact that researchers observed a 50 percent decrease in severe sporadic or cumulative neuropathy. "A surprising and medically important observation from the trial was an observed increase in the median survival time for patients receiving Tavocept as compared to those receiving placebo." Release

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.